



# Iceland

## Recent and planned developments in pharmaceutical policies 2014 Policies related to high cost medicines

<b>D E V E L O P M E N T S</b>	<b>Changes in pricing</b>	<b>Changes in reimbursement</b>
	<p>Pharmacy margins increased 1st. of January 2014 by 3,9% on the fixed handling fee. The margin for medicines with wholesale price upto 75 Euro have a 9% margin plus a 5,5 Euro handling fee. All other medicine has a handling fee of 14 Euro</p> <p>Price review and reduction of the ATC groups G03BA, N06BA and C03EA01 in 2014.</p> <p>Price review of the total pricelist is planned in 2015. Review of wholesale POM prices will conducted in February/March and implemented in the pricelist in April/May. POM prices are compared to prices in Denmark, Finland, Norway and Sweden. Wholesale prices in the price list can be connected to a foreign currency and are change monthly accordingly.</p> <p>Review of Hospital drugs wholesale prices will be reviewed in February 2015 and implemented in the pricelist in April. Prices of hospital drugs are compared to the lowest price in to prices in Denmark, Finland, Norway and Sweden.</p>	<p>Review of the reimbursement of the ATC group B01A the new anti-coagulants and also review of reimbursement of acne medication November/December 2014.</p> <p>It is planned that a High-cost medicines and hospital drugs on prescription will go into the co-payment system as from 1st. of January 2015</p>
<b>Other changes</b> New co-payment system for all health care service		
<b>S P E C I A L  T O P I C</b>	<b>High cost medicines</b>	
	<ul style="list-style-type: none"> <li>• <u>Special pricing policies:</u> Yes-same as for hospital drugs - Prices of high cost medicines are compared to the lowest price in to prices in Denmark, Finland, Norway and Sweden.</li> <li>• <u>Special reimbursement/funding policies:</u> There is allocated budget for high cost medicines for ambulatory patients.</li> <li>• <u>High cost medicines at the interface of out-patient and in-patient sectors:</u></li> <li>• Dual co-payment for all medicines in Iceland. Out-patients are reimbursed by National Health Insurance, inpatients free of charge.</li> <li>• Tri-fold financing for all medicines Iceland:             <ul style="list-style-type: none"> <li>• In the out-patient sector: General medicines included in the copayment system and reimbursed by the National Health Insurance.</li> <li>• In the in-patient sector: Medicines are funded via fixed budget.</li> <li>• For a list of high cost medicines and certain hospital drugs for ambulant patients, there is a funding agreement between the University hospital and National Health Insurance.</li> </ul> </li> <li>• <u>Key challenges and solutions:</u> <ul style="list-style-type: none"> <li>• Increasing cost and number of patients of new high cost medicines and transparency in decision-making.</li> </ul> </li> </ul> <p><u>Solution: cooperation between countries:</u> It has been proposed that the Nordic Council of Ministers establish a permanent Nordic Coordination Group for Value Based Assessment of high cost medicines and for cooperation on other issues regarding high cost medicines that are of common interest. Coordinated activities on the access of the hepatitis C medicines initiated by Italy.</p> <ul style="list-style-type: none"> <li>• Medicines at the interface of the out-patient and in-patient sectors.</li> </ul> <p><u>Solutions:</u> High-cost medicines and hospital drugs on prescription for ambulant patients will go into the co-payment system as from 1st. of January 2015.</p>	